|Gilbert Dupont||Guillaume Cuvillier||Equity Research Analyst
|Rx Securities||Samir Devani||Managing Director
London, United Kingdom
+44 207 993 8210
|Genesta||Jean-Pierre Loza||Financial Analyst
+33 145 63 68 87
Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Paris and Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France.
© 2019 Advicenne